31 C
Vientiane
Tuesday, April 29, 2025
spot_img
Home Blog Page 550

Vantage Markets Recognized at the Global Brands Magazine Awards 2025

PORT VILA, Vanuatu, Feb. 17, 2025 /PRNewswire/ — Vantage Markets is honored to announce its recognition at the Global Brands Magazine (GBM) Awards 2025, where it has been acknowledged for – “Best CFD Broker, APAC 2025” and “Best Forex Affiliate Program, Global 2025”.

Vantage Markets Recognized at the Global Brands Magazine Awards 2025
Vantage Markets Recognized at the Global Brands Magazine Awards 2025

These awards highlight Vantage’s commitment to developing innovative solutions and fostering strong partnerships in the financial markets.

Global Brands Magazine (GBM) is a leading publication dedicated to recognizing excellence across industries. Now in its 13th edition, the GBM Awards celebrate brands that have demonstrated outstanding performance, exceptional service, and a visionary approach in their respective sectors.

The Forex Awards, conducted annually by GBM, aim to highlight brokers that deliver best-in-class trading experiences, technological advancements, and superior customer service. A dedicated external research team was responsible for evaluating the nominees, with Vantage standing out for its remarkable commitment to quality, branding, and innovation in the forex and CFD trading space.

The acknowledgment for “Best CFD Broker, APAC 2025” underscores Vantage’s efforts to enhance its trading environment, technological infrastructure, and educational resources to support traders of all levels.

Vantage’s focus on low-latency execution, competitive spreads, multi-asset trading, and exceptional customer support has made it a recognized broker, providing seamless, transparent, and efficient trading experience.

The recognition for “Best Forex Affiliate Program, Global 2025” highlights Vantage’s dedication to creating rewarding partnerships with affiliates. Through its affiliate program, Vantage offers partners:

  • Competitive commission structures that aim to optimize earning potential
  • Advanced tracking and reporting tools for full transparency
  • Comprehensive marketing support
  • A dedicated affiliate management team supporting our partners

Marc Despallieres, CEO of Vantage Markets, shared his thoughts on this recognition: These acknowledgments from Global Brands Magazine reflect our commitment to excellence in both trading and partnerships. We strive to offer our clients a high-quality trading environment and to provide our affiliates with effective tools and support to grow their businesses. This recognition inspires us to continue pushing the boundaries of innovation and service in the financial markets.”

With these new acknowledgments, Vantage reaffirms its dedication to providing traders with cutting-edge solutions, transparency, and a client-first approach. As the company continues to develop globally, it remains focused on enhancing its offerings, fostering strong partnerships, and maintaining high standards in the forex and CFD industry.

For more details on Vantage’s award-winning services and partnership programs, visit Vantage Markets.

About Vantage

Vantage Markets (or Vantage) is a multi-asset CFD broker offering clients access to a nimble and powerful service for trading Contracts for Difference (CFDs) products, including Forex, Commodities, Indices, Shares, ETFs, and Bonds.

With over 15 years of market experience, Vantage transcends the role of broker, providing a trusted trading ecosystem, an award-winning mobile trading app, and a user-friendly trading platform that empowers clients to seize trading opportunities. Download the Vantage App on App Store or Google Play.

trade smarter @vantage

Important Notice: This article is for informational purposes only and does not constitute an offer or solicitation of Vantage’s services in any jurisdiction where Vantage is not authorized to operate. Vantage’s services may not be available in all regions, and are subject to local regulatory requirements. Before engaging with our services, please consult your local regulations to ensure eligibility.

RISK WARNING: CFD trading carries significant risks. You could lose more than your initial investment.

State Grid Shizuishan Power Supply Company’s intelligent distribution network construction significantly enhances the reliability and efficiency of electricity supply, facilitating critical upgrades

SHIZUISHAN, China, Feb. 17, 2025 /PRNewswire/ — Recently, the company achieved a significant milestone in smart distribution network development by successfully implementing real-time measurements for the “one-click load transfer” function during large-scale outages across 19 key local guaranteed lines. This innovative measure enables rapid load transfer within seconds, thereby enhancing emergency response capabilities and meeting the stringent power supply requirements for the region’s rapid economic and social development.

To ensure optimal operation of the intelligent distribution network, State Grid Shizuishan Power Supply Company has undertaken comprehensive structural optimization of the distribution network framework. This includes eliminating redundant connections, optimizing line valuation, and upgrading numerous distribution terminals. Additionally, the company has standardized the “one-click load transfer” process and developed a detailed operational manual to facilitate the widespread adoption of standardized intelligent distribution practices.

In early 2025, leveraging the opportunities presented by New Year’s Day, the Spring Festival, and the National Two Sessions, State Grid Shizuishan Power Supply Company intensified its efforts in maintaining and operating distribution automation systems. The company pioneered the use of the “group control” function in the new generation of distribution automation systems, efficiently addressing terminal battery defects in distribution equipment and ensuring the reliable operation of these systems.

Moving forward, State Grid Shizuishan Power Supply Company will continue to deepen research and innovation in distribution automation. The company is committed to exploring advanced technologies such as priority trial delivery FA and group intelligent collaborative reactive power optimization and control strategies. Through continuous technological advancements and optimized management practices, State Grid Shizuishan Power Supply Company aims to provide robust power support for the region’s high-quality development.

Sikhai-Sikeuth Highway Upgrade to Complete by March End

Sikhai-Sikeuth Highway Upgrade to Complete by March End
Sikhai-Sikeuth Highway Upgrade to Complete by March End

The paving of the northern section of National Road 13’s 6.3-kilometer Sikhai-Sikeuth highway in Vientiane is nearing completion and is expected to be finished by the end of March, according to Dalavieng Chanthalangsy, Project Manager for the highway upgrade.

This section stretches between Sikhottabong and Naxaithong districts. 

Currently, crews are laying concrete between the Sikhai and Dongnathong junctions, Dalavieng noted on 12 February. The remaining work—including curbs, footpaths, and lane markings—is on schedule to be completed by 31 March, in line with the original plan.

Sikhai-Sikeuth Highway Upgrade Project
Sikhai-Sikeuth Highway Upgrade Project

As part of the broader improvements, sections of National Road 13 are also being widened and resurfaced with concrete, including a 58-kilometer stretch between Sikeuth village and Phonhong district’s National Road 13 (North). The upgrade will expand the road from two to four lanes, with a two-meter-wide median strip, motorcycle lanes on both sides, and 1.5-meter-wide sidewalks.

The USD 10.29 million project also includes streetlights, closed drainage ditches, and other infrastructure enhancements. It is part of the ongoing improvements to northern National Road 13, a vital route connecting China to Cambodia through Laos.

Tangchaleun Group Co., Ltd. is leading the construction in collaboration with Dongsung, Dasan Consulting (South Korea), and Lao Consulting Group. The project has an 18-month construction period, followed by a three-year maintenance phase. Funding is provided by the World Bank, the Asian Infrastructure Investment Bank, the Nordic Development Fund, and the Lao government.

Boldyn Networks appoints Sara Dickinson as Group CFO

The executive brings significant experience in critical finance roles at sizeable companies

LONDON, Feb. 17, 2025 /PRNewswire/ — Boldyn Networks (Boldyn), one of the world’s largest shared network infrastructure providers, announced the appointment of Sara Dickinson as Group Chief Financial Officer (CFO). Sara brings significant experience in critical finance roles across both public and private sectors. She joins Boldyn from BSI, where she served as Group CFO for the past three years.

Sara Dickinson, Boldyn Networks Group CFO
Sara Dickinson, Boldyn Networks Group CFO

At BSI, a global services company operating in over 60 countries, Sara led a significant transformation of the business and operating model. Prior to BSI, she spent five years at Expedia Group in senior finance roles, including SVP Finance and CFO for the B2B division, where she guided the business through a high-growth phase. Her extensive experience includes senior executive roles at Costa Coffee and Sage plc, further demonstrating her capability in leading financial strategies and operations.

Igor Leprince, Boldyn Networks Group CEO said: “I am delighted to welcome Sara to our executive team during this exciting phase for our business. She is not only a proven CFO with extensive experience in complex international businesses with digital and technological components, but she also excels in guiding companies through growth, transformation, and acquisitions. Sara’s expertise in leading change is invaluable. Furthermore, she aligns perfectly with our culture and values at Boldyn.”

“I’d like to extend my heartfelt thanks to Stephen Matthews for his close to 12 incredible years of financial leadership, which have been pivotal in Boldyn’s integration, growth and success. As Stephen returns home to Australia, he will play a crucial role in onboarding Sara to her new position, where she will oversee our Group Finance and Legal functions”, he continued.

“I’m very excited to join Boldyn Networks and support the company’s unstoppable growth, driven by its strong values”, said Sara Dickinson, Group CFO at Boldyn Networks. “Boldyn is a game changer in the technology industry and is disrupting many sectors with shared connectivity that’s sustainable and cost efficient. I’m thrilled to be part of this journey.”

 

Weibo Corporation to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025

BEIJING, Feb. 17, 2025 /PRNewswire/ — Weibo Corporation (Nasdaq: WB and HKEX: 9898), a leading social media for people to create, share and discover content, will announce its unaudited financial results for the fourth quarter and fiscal year 2024 before the U.S. market opens on Thursday, March 13, 2025. Following the announcement, Weibo’s management team will host a conference call from 7 AM8 AM Eastern Time on March 13, 2025 (or 7 PM8 PM Beijing Time on March 13, 2025) to present an overview of the Company’s financial performance and business operations.

Participants who wish to dial in to the teleconference must register through the below public participant link. Dial in and instruction will be in the confirmation email upon registering.

Participants Registration Link: https://register.vevent.com/register/BIf3e83e2236a24ff5839823fdb84a4a1f

Additionally, a live and archived webcast of this conference call will be available at http://ir.weibo.com.

About Weibo Corporation

Weibo is a leading social media for people to create, share and discover content online. Weibo combines the means of public self-expression in real time with a powerful platform for social interaction, content aggregation and content distribution. Any user can create and post a feed and attach multi-media and long-form content. User relationships on Weibo may be asymmetric; any user can follow any other user and add comments to a feed while reposting. This simple, asymmetric and distributed nature of Weibo allows an original feed to become a live viral conversation stream.

Weibo enables its advertising and marketing customers to promote their brands, products and services to users. Weibo offers a wide range of advertising and marketing solutions to companies of all sizes. The Company generates a substantial majority of its revenues from the sale of advertising and marketing services, including the sale of social display advertisement and promoted marketing offerings. Designed with a “mobile first” philosophy, Weibo displays content in a simple information feed format and offers native advertisement that conform to the information feed on our platform. To support the mobile format, we have developed and continuously refining our social interest graph recommendation engine, which enables our customers to perform people marketing and target audiences based on user demographics, social relationships, interests and behaviors, to achieve greater relevance, engagement and marketing effectiveness

Contact:
Investor Relations
Weibo Corporation
Phone: +86 10 5898-3336
Email: ir@staff.weibo.com

Japan Festival Celebrates 70th Anniversary of Japan-Laos Diplomatic Relations

Japan Ambassader and Lao government took a picture with the Shishimai (Japanese lion dance) by Takafuji Ukon

Thousands of locals, residents and visitors have been treated to the sights, sounds and tastes of Japan at the 2025 Japan Festival in Vientiane Capital on 14-15 February

Fosun Pharmaceutical Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation

SHANGHAI, Feb. 17, 2025 /PRNewswire/ — Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transformative potential of AI technology in the pharmaceutical and healthcare sectors. The company actively embraces AI technology, deploying it in areas such as drug research and development, medical imaging, and precision medicine through both independent research and external collaborations, thereby driving transformation and development in the pharmaceutical industry through technological advancements. At the same time, Fosun Pharma is accelerating the deeper application of AI technology in marketing, customer service, and smart office solutions, using AI to improve quality and efficiency while promoting enhanced corporate management effectiveness.

Fosun Pharma's Layout in AI Field
Fosun Pharma’s Layout in AI Field

Self-developed PharmAID Decision Intelligence Platform Integrates Global Leading Large Model Technology and Has connected with Deepseek R1

As a pioneer in the AI transformation of the pharmaceutical industry, Fosun Pharma recently launched its self-developed PharmAID decision intelligence platform internally. This platform establishes a full lifecycle intelligent decision-making network covering innovative R&D scenarios. Deeply integrated with global leading large model technologies, the platform has taken the lead in connecting to with Deepseek R1. Based on the PharmAID decision intelligence platform, Fosun Pharma is accelerating the development of “drug commercial value-assisted decision-making” capabilities, broadening decision-making perspectives, and improving decision accuracy. The platform enhances drug R&D efficiency and accelerates the transformation of R&D achievements by integrating point prediction, conformational prediction, binding mechanism analysis, toxicology optimization, medical writing, and clinical information extraction. This initiative aims to lead innovation and transformation, and it is the first self-developed AI decision intelligence platform in pharmaceutical industry.

The PharmAID decision intelligence platform offers AI translation and AI medical writing/revision features, significantly improving information retrieval and writing efficiency under the support of AI technology. At present, the PharmAID decision intelligence platform has integrated multiple professional clinical information and pipeline data platforms around the world, increasing content generation accuracy in the pharmaceutical and healthcare field by 50% compared to general large models, with data updated at T+1, ensuring outstanding accuracy and timeliness. Moreover, Fosun Pharma applies AI technology to carry out intelligent training for sales personnel and further assists business scenarios, achieving “more precise” marketing. Through the deep empowerment of the PharmAID decision intelligence platform, Fosun Pharma is building its digital competitiveness, leading the entire pharmaceutical industry into a new era of AI-driven innovation.

AI Technology Empowers Innovative R&D and Accelerate Breakthroughs

Fosun Pharma actively promotes AI-driven innovation. As early as 2022, Fosun Pharma formed a strategic partnership with AI pharmaceutical company Insilico Medicine, combining strengths to embark on a new journey in global AI drug R&D. In January 2025, Henlius, a subsidiary of Fosun Pharma, entered into a strategic collaboration with DP Technology for AI-assisted drug R&D, aiming to integrate AI with physical modeling to jointly advance new drug development processes. This collaboration leverages DP Technology’s technical strength and project experience in the “AI for Science” field, combining expertise in drug discovery and AI computing to provide new insights for the development of biologics antibodies/ADCs and small molecule drugs targeting difficult-to-drug targets.

Building an “AI+X” Smart Healthcare Ecosystem

In medical devices sector, Fosun Aitrox, a subsidiary of Fosun Pharma, focuses on the medical AI field and is one of the few companies in China offering comprehensive AI medical service solutions across multiple departments including radiology, pathology, ultrasound, cardiology, respiratory, orthopedics, neurology, and thyroid and breast surgery. Fosun Aitrox delves into medical institutions and primary healthcare service scenarios, identifying real needs and enhancing service capabilities in core scenarios of tiered healthcare systems, including early screening, remote diagnosis, and precision medicine. Through the “AI+X” model, Fosun Aitrox collaborates deeply with top medical centers, promoting the transformation of scientific research achievements and the popularization of standardized medical systems, empowering the construction of smart diagnosis and treatment systems. Its three major AI-assisted diagnostic product lines—radiology imaging, pathology imaging, and ultrasound imaging—have been widely used clinically and have won multiple world championships in international competitions.

Fosun Aitrox’s AI medical imaging products can quickly and accurately analyze medical imaging data, providing doctors with diagnostic suggestions, helping them more efficiently identify lesions and assess conditions, thereby improving diagnostic accuracy and timeliness. The application of this technology not only enhances the quality and efficiency of medical services but also benefits patients in remote and resource-scarce areas, allowing them to access high-quality medical services locally. To date, Fosun Aitrox has expanded its presence to cover 70% of China, with operating businesses in over 20 provinces, establishing nearly 10 regional smart healthcare project models. The company has released and is developing more than 70 AI products.

Additionally, Fosun Pharma’s incubated company, JeDiCare, leverages its extensive experience in image navigation algorithm development and interventional consumable design, along with a global perspective, to innovatively introduce AR navigation technology into minimally invasive surgery. Its self-developed puncture surgery navigation device (AR navigation puncture positioning system) is currently under market application review. This product features proprietary “monocular vision augmented reality” technology, integrating computer vision monocular tracking and AR display technology, not only achieving precise positioning but also optimizing the positioning process. In the future, with the assistance of the AR navigation puncture positioning system, primary hospitals will also be able to perform precise thoracoscopic surgeries, bringing high-quality medical care to more patients.

Looking ahead, Fosun Pharma will continue to increase investment and exploration in AI, accelerating the construction of AI innovation across the entire industry chain through independent research and external collaborations, leading the AI transformation of the pharmaceutical industry, and contributing more wisdom and strength to the cause of human health.

***

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma’s innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of “Innovation for Good Health”, continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation.

For more information, please visit our official website: www.fosunpharma.com

 

Fosun Pharma Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation

SHANGHAI, Feb. 17, 2025 /PRNewswire/ — Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transformative potential of AI technology in the pharmaceutical and healthcare sectors. The company actively embraces AI technology, deploying it in areas such as drug research and development, medical imaging, and precision medicine through both independent research and external collaborations, thereby driving transformation and development in the pharmaceutical industry through technological advancements. At the same time, Fosun Pharma is accelerating the deeper application of AI technology in marketing, customer service, and smart office solutions, using AI to improve quality and efficiency while promoting enhanced corporate management effectiveness.

Fosun Pharma's Layout in AI Field
Fosun Pharma’s Layout in AI Field

Self-developed PharmAID Decision Intelligence Platform Integrates Global Leading Large Model Technology and Has connected with Deepseek R1

As a pioneer in the AI transformation of the pharmaceutical industry, Fosun Pharma recently launched its self-developed PharmAID decision intelligence platform internally. This platform establishes a full lifecycle intelligent decision-making network covering innovative R&D scenarios. Deeply integrated with global leading large model technologies, the platform has taken the lead in connecting to with Deepseek R1. Based on the PharmAID decision intelligence platform, Fosun Pharma is accelerating the development of “drug commercial value-assisted decision-making” capabilities, broadening decision-making perspectives, and improving decision accuracy. The platform enhances drug R&D efficiency and accelerates the transformation of R&D achievements by integrating point prediction, conformational prediction, binding mechanism analysis, toxicology optimization, medical writing, and clinical information extraction. This initiative aims to lead innovation and transformation, and it is the first self-developed AI decision intelligence platform in pharmaceutical industry.

The PharmAID decision intelligence platform offers AI translation and AI medical writing/revision features, significantly improving information retrieval and writing efficiency under the support of AI technology. At present, the PharmAID decision intelligence platform has integrated multiple professional clinical information and pipeline data platforms around the world, increasing content generation accuracy in the pharmaceutical and healthcare field by 50% compared to general large models, with data updated at T+1, ensuring outstanding accuracy and timeliness. Moreover, Fosun Pharma applies AI technology to carry out intelligent training for sales personnel and further assists business scenarios, achieving “more precise” marketing. Through the deep empowerment of the PharmAID decision intelligence platform, Fosun Pharma is building its digital competitiveness, leading the entire pharmaceutical industry into a new era of AI-driven innovation.

AI Technology Empowers Innovative R&D and Accelerate Breakthroughs

Fosun Pharma actively promotes AI-driven innovation. As early as 2022, Fosun Pharma formed a strategic partnership with AI pharmaceutical company Insilico Medicine, combining strengths to embark on a new journey in global AI drug R&D. In January 2025, Henlius, a subsidiary of Fosun Pharma, entered into a strategic collaboration with DP Technology for AI-assisted drug R&D, aiming to integrate AI with physical modeling to jointly advance new drug development processes. This collaboration leverages DP Technology’s technical strength and project experience in the “AI for Science” field, combining expertise in drug discovery and AI computing to provide new insights for the development of biologics antibodies/ADCs and small molecule drugs targeting difficult-to-drug targets.

Building an “AI+X” Smart Healthcare Ecosystem

In medical devices sector, Fosun Aitrox, a subsidiary of Fosun Pharma, focuses on the medical AI field and is one of the few companies in China offering comprehensive AI medical service solutions across multiple departments including radiology, pathology, ultrasound, cardiology, respiratory, orthopedics, neurology, and thyroid and breast surgery. Fosun Aitrox delves into medical institutions and primary healthcare service scenarios, identifying real needs and enhancing service capabilities in core scenarios of tiered healthcare systems, including early screening, remote diagnosis, and precision medicine. Through the “AI+X” model, Fosun Aitrox collaborates deeply with top medical centers, promoting the transformation of scientific research achievements and the popularization of standardized medical systems, empowering the construction of smart diagnosis and treatment systems. Its three major AI-assisted diagnostic product lines—radiology imaging, pathology imaging, and ultrasound imaging—have been widely used clinically and have won multiple world championships in international competitions.

Fosun Aitrox’s AI medical imaging products can quickly and accurately analyze medical imaging data, providing doctors with diagnostic suggestions, helping them more efficiently identify lesions and assess conditions, thereby improving diagnostic accuracy and timeliness. The application of this technology not only enhances the quality and efficiency of medical services but also benefits patients in remote and resource-scarce areas, allowing them to access high-quality medical services locally. To date, Fosun Aitrox has expanded its presence to cover 70% of China, with operating businesses in over 20 provinces, establishing nearly 10 regional smart healthcare project models. The company has released and is developing more than 70 AI products.

Additionally, Fosun Pharma’s incubated company, JeDiCare, leverages its extensive experience in image navigation algorithm development and interventional consumable design, along with a global perspective, to innovatively introduce AR navigation technology into minimally invasive surgery. Its self-developed puncture surgery navigation device (AR navigation puncture positioning system) is currently under market application review. This product features proprietary “monocular vision augmented reality” technology, integrating computer vision monocular tracking and AR display technology, not only achieving precise positioning but also optimizing the positioning process. In the future, with the assistance of the AR navigation puncture positioning system, primary hospitals will also be able to perform precise thoracoscopic surgeries, bringing high-quality medical care to more patients.

Looking ahead, Fosun Pharma will continue to increase investment and exploration in AI, accelerating the construction of AI innovation across the entire industry chain through independent research and external collaborations, leading the AI transformation of the pharmaceutical industry, and contributing more wisdom and strength to the cause of human health.

***

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma’s innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of “Innovation for Good Health”, continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation.

For more information, please visit our official website: www.fosunpharma.com